Eloxx Pharmaceuticals vs Molecular Partners
ELOX and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELOX and MOLN compare
Eloxx Pharmaceuticals grew revenue faster over the last twelve months (−100% versus −100% for Molecular Partners).
Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELOX | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $52.5M | – |
| Share price | $13.01 | $3.09 |
| Change, 1 year | 1182630% | −27.3% |
| Change, 5 years | −97.8% | −70.4% |
| Beta (5Y) | – | 0.90 |
| Employees | 7 | 34 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.1× | – |
| Growth | ||
| Revenue growth (TTM) | −100% | −100% |
| Profitability | ||
| Return on equity | −54.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 3.74 | 7.27 (better) |
| Altman Z-score | −4.42 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 71.8% | 8.9% |
| Held by insiders | 42.6% | 0.00% |
| Short interest, % of float | 2.3% | – |
Go deeper
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.